Seres Therapeutics Inc
F:1S9
Balance Sheet
Balance Sheet Decomposition
Seres Therapeutics Inc
Seres Therapeutics Inc
Balance Sheet
Seres Therapeutics Inc
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash & Cash Equivalents |
2
|
114
|
74
|
55
|
36
|
86
|
65
|
116
|
180
|
163
|
128
|
31
|
|
| Cash Equivalents |
2
|
114
|
74
|
55
|
36
|
86
|
65
|
116
|
180
|
163
|
128
|
31
|
|
| Short-Term Investments |
0
|
0
|
131
|
139
|
114
|
0
|
30
|
138
|
111
|
18
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
9
|
0
|
0
|
9
|
2
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
9
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
30
|
0
|
|
| Other Current Assets |
0
|
0
|
3
|
5
|
5
|
7
|
4
|
6
|
13
|
13
|
9
|
6
|
|
| Total Current Assets |
2
|
114
|
208
|
198
|
155
|
93
|
100
|
269
|
304
|
195
|
175
|
39
|
|
| PP&E Net |
0
|
1
|
8
|
36
|
33
|
26
|
31
|
23
|
36
|
134
|
132
|
92
|
|
| PP&E Gross |
0
|
1
|
8
|
36
|
33
|
26
|
31
|
23
|
36
|
134
|
132
|
92
|
|
| Accumulated Depreciation |
0
|
0
|
1
|
5
|
12
|
20
|
28
|
34
|
40
|
45
|
51
|
53
|
|
| Long-Term Investments |
0
|
0
|
0
|
37
|
0
|
0
|
0
|
50
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
2
|
2
|
1
|
2
|
2
|
1
|
1
|
15
|
20
|
51
|
9
|
|
| Total Assets |
2
N/A
|
117
+5 422%
|
217
+85%
|
273
+26%
|
190
-30%
|
120
-36%
|
132
+10%
|
343
+159%
|
355
+3%
|
349
-2%
|
359
+3%
|
140
-61%
|
|
| Liabilities | |||||||||||||
| Accounts Payable |
0
|
2
|
5
|
8
|
7
|
6
|
5
|
4
|
14
|
17
|
4
|
4
|
|
| Accrued Liabilities |
0
|
1
|
3
|
4
|
5
|
5
|
9
|
12
|
16
|
18
|
23
|
34
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
1
|
3
|
19
|
20
|
31
|
32
|
30
|
53
|
49
|
72
|
3
|
|
| Total Current Liabilities |
1
|
5
|
11
|
30
|
32
|
42
|
46
|
46
|
82
|
86
|
99
|
41
|
|
| Long-Term Debt |
0
|
1
|
0
|
0
|
0
|
0
|
25
|
25
|
25
|
51
|
102
|
0
|
|
| Other Liabilities |
0
|
2
|
1
|
110
|
97
|
126
|
110
|
97
|
116
|
202
|
203
|
85
|
|
| Total Liabilities |
2
N/A
|
8
+382%
|
12
+44%
|
140
+1 117%
|
129
-8%
|
169
+31%
|
181
+7%
|
168
-7%
|
223
+33%
|
338
+51%
|
403
+19%
|
126
-69%
|
|
| Equity | |||||||||||||
| Common Stock |
12
|
136
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
11
|
28
|
83
|
174
|
264
|
389
|
460
|
549
|
614
|
865
|
978
|
978
|
|
| Additional Paid In Capital |
0
|
1
|
288
|
307
|
324
|
341
|
411
|
723
|
746
|
875
|
933
|
992
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
0
N/A
|
109
+23 317%
|
205
+88%
|
133
-35%
|
61
-54%
|
48
N/A
|
48
-1%
|
175
N/A
|
132
-25%
|
11
-92%
|
45
N/A
|
14
N/A
|
|
| Total Liabilities & Equity |
2
N/A
|
117
+5 422%
|
217
+85%
|
273
+26%
|
190
-30%
|
120
-36%
|
132
+10%
|
343
+159%
|
355
+3%
|
349
-2%
|
359
+3%
|
140
-61%
|
|
| Shares Outstanding | |||||||||||||
| Common Shares Outstanding |
2
|
2
|
2
|
2
|
2
|
2
|
4
|
5
|
5
|
6
|
7
|
9
|
|